Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes

Cancer Research

Volumn 59, Issue 21, 1999, Pages 5433-5437

  Melillo, Giovanni ^a,c   Sausville, Edward A ^a   Cloud, Kiona ^a   Lahusen, Tyler ^a   Varesio, Luigi ^b   Senderowicz, Adrian M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b G GASLINI INSTITUTE   (Italy)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVOPIRIDOL; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL HYPOXIA; DOWN REGULATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MOLECULAR STABILITY; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ANOXIA; BLOTTING, NORTHERN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; LUCIFERASES; LYMPHOKINES; MONOCYTES; PIPERIDINES; PROTEIN KINASE INHIBITORS; RNA, MESSENGER; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033231301     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Wahl, L. M., and Kleinman, H. K. Tumor-associated macrophages as targets for cancer therapy [see Comment]. J. Natl. Cancer Inst., 90: 1583-1584, 1998.
2. Ratcliffe, P. J., O'Rourke, J. F., Maxwell, P. H., and Pugh, C. W. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J. Exp. Biol., 201: 1153-1162, 1998.
3. Semenza, G. L. Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis. J. Lab. Clin. Med., 131: 207-214, 1998.
4. Wenger, R. H., and Gassmann, M. Oxygen(es) and the hypoxia-inducible factor-1. Biol. Chem., 378: 609-616, 1997.
5. Levy, A. P., Levy, N. S., and Goldberg, M. A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem., 271: 2746-2753, 1996.
6. Melillo, G., Musso, T., Sica, A., Taylor, L. S., Cox, G. W., and Varesio, L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J. Exp. Med., 182: 1683-1693, 1995.
7. Ferrara, N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top. Microbiol. Immunol., 237: 1-30, 1999.
8. Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., and Semenza, G. L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol., 16: 4604-4613, 1996.
9. Stein, I., Neeman, M., Shweiki, D., Itin, A., and Keshet, E. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol. Cell. Biol., 15: 5363-5368, 1995.
10. Levy, N. S., Chung, S., Furneaux, H., and Levy, A. P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem., 273: 6417-6423, 1998.
11. Shih, S. C., and Claffey, K. P. Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J. Biol. Chem., 274: 1359-1365, 1999.
12. Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., Arbuck, S. G., and Sausville, E. A. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol., 16: 2986-2999, 1998.
13. De Azevedo, W. F., Jr., Mueller-Dieckmann, H. J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., and Kim, S. H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA, 93: 2735-2740, 1996.
14. Sedlacek, H. H., Czech, J., Naik, R., Kaur, G., Worland, P. J., Losiewicz, M. D., Parker, B. W., Carlson, B. A., Smith, A., Senderowicz, A. M., and Sausville, E. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol., 9: 1143-1168, 1996.
15. Carlson, B. A., Dubay, M. M., Sausville, E. A., Brizuela, L., and Worland, P. J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res., 56: 2973-2980, 1996.
16. Drees, M., Dengle, W. A., Roth, T., Labonte, H., Mayo, J., Malspeis, L., Grever, M., Sausville, E. A., and Fiebig, H. H. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin. Cancer Res., 3: 273-279, 1999.
17. Patel, V., Senderowicz, A. M., Pinto, D., Jr., Igishi, T., Raffeld, M., Quintanilla-Martinez, L., Ensley, J. F., Sausville, E. A., and Gutkind, J. S. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Investig. 102: 1674-1681, 1998.
18. Arguello, F., Alexander, M., Sterry, J. A., Tudor, G., Smith, E. M., Kalavar, N. T., Greene, J. F., Jr., Koss, W., Morgan, C. D., Stinson, S. F., Siford, T. J., Alvord, W. G., Klabansky, R. L., and Sausville, E. A. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood, 91: 2482-2490, 1998.
19. Parker, B. W., Kaur, G., Nieves-Neira, W., Taimi, M., Kohlhagen, G., Shimizu, T., Losiewicz, M. D., Pommier, Y., Sausville, E. A., and Senderowicz, A. M. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood, 91: 458-465, 1998.
20. Czerniecki, B. J., Carter, C., Rivoltini, L., Koski, G. K., Kim, H. I., Weng, D. E., Roros, J. G., Hijazi, Y. M., Xu, S., Rosenberg, S. A., and Cohen, P. A. Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J. Immunol., 159: 3823-3837, 1997.
21. Mazure, N. M., Chen, E. Y., Laderoute, K. R., and Giaccia, A. J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/ Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood, 90: 3322-3331, 1997.
22. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA, 95: 7987-7992, 1998.